Prostate Cancer
Reports


Volume 7 Number 4
April 2019


Home > Disciplines > Publications > Prostate Cancer Reports > Volume 7, Year 2019 > Number 4, April



CONTENTS


CASE REPORTS
DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS, PREVENTION
ETIOLOGY, PATHOGENESIS, PATHOLOGY
FOLLOW-UP, QUALITY OF LIFE
INTEGRATIVE MEDICINE
PROGNOSIS
TREATMENT



CASE REPORTS

.

Vaishampayan U, Shi D, Abdulfatah E, Aoun H, Wynberg J.
Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer.
Urol Case Rep. 2019 Jan 28;23:103-105. doi: 10.1016/j.eucr.2019.01.018. eCollection 2019 Mar.
Source | Full text | Similar articles



DIAGNOSIS

.

Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S.
Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy.
Ann Nucl Med. 2019 Feb 18. doi: 10.1007/s12149-019-01340-1. [Epub ahead of print]
Source | Full text | Similar articles



.

Houlahan KE, Salmasi A, Sadun TY, Pooli A, Felker ER, Livingstone J, Huang V, Raman SS, Ahuja P, Sisk AE Jr, Boutros PC, Reiter RE.
Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.
Eur Urol. 2019 Jan 24. pii: S0302-2838(18)31044-3. doi: 10.1016/j.eururo.2018.12.036. [Epub ahead of print]
Source | Full text | Similar articles



.

Kam J, Yuminaga Y, Krelle M, Gavin D, Koschel S, Aluwihare K, Sutherland T, Skinner S, Brennan J, Wong LM, Louie-Johnsun M.
Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an australian multicentre study.
BJU Int. 2019 Feb 3. doi: 10.1111/bju.14696. [Epub ahead of print]
Source | Full text | Similar articles



.

Shoag JE, Tosoian JJ, Salami SS, Barbieri CE.
Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility.
Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30070-3. doi: 10.1016/j.eururo.2019.01.027. [Epub ahead of print]
Source | Full text | Similar articles
Referring to: Houlahan KE et al., Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer. Eur Urol. 2019 Jan 24. pii: S0302-2838(18)31044-3. doi: 10.1016/j.eururo.2018.12.036. [Epub ahead of print]. Source , Full text



.

Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ, Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED, Davis BJ, Nathan MA.
Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.
Adv Radiat Oncol. 2018 Sep 4;4(1):79-89. doi: 10.1016/j.adro.2018.08.022. eCollection 2019 Jan-Mar.
Source | Full text | Similar articles



EPIDEMIOLOGY, RISK FACTORS, PREVENTION

.

De Nunzio C, Brassetti A, Simone G, Lombardo R, Mastroianni R, Collura D, Muto G, Gallucci M, Tubaro A.
Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study.
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):438-445. doi: 10.1038/s41391-018-0054-9. Epub 2018 Jun 4. Erratum in: Prostate Cancer Prostatic Dis. 2019 Feb 1
Source | Full text | Similar articles | Erratum



.

Ho W, Choo DW, Wu YJ, Chan TF, Lin ZF.
Statins Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan.
Clin Pharmacol Ther. 2019 Feb 22. doi: 10.1002/cpt.1408. [Epub ahead of print]
Source | Full text | Similar articles



.

Yoo S, Oh S, Park J, Cho SY, Cho MC, Son H, Jeong H.
Effects of metabolic syndrome on the prevalence of prostate cancer: historical cohort study using the national health insurance service database.
J Cancer Res Clin Oncol. 2019 Mar;145(3):775-780. doi: 10.1007/s00432-019-02842-1. Epub 2019 Jan 17.
Source | Full text | Similar articles



ETIOLOGY, PATHOGENESIS, PATHOLOGY

.

Wang W, Yang X, Dai J, Lu Y, Zhang J, Keller ET.
Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.
Oncogene. 2019 Feb 12. doi: 10.1038/s41388-019-0736-3. [Epub ahead of print]
Source | Full text | Similar articles



FOLLOW-UP, QUALITY OF LIFE

.

Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E, Wagland R, Kind P, Donnelly DW, Butcher H, Catto JWF, Cross W, Mason M, Sharp L, Weller D, Velikova G, McCaughan E, Mottram R, Allen M, Kearney T, McSorley O, Huws DW, Brewster DH, McNair E, Gavin A, Glaser AW.
Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.
Lancet Oncol. 2019 Mar;20(3):436-447. doi: 10.1016/S1470-2045(18)30780-0. Epub 2019 Jan 31.
Source | Full text | Similar articles



.

Manfredi M, Checcucci E, Fiori C, Garrou D, Aimar R, Amparore D, De Luca S, Bombaci S, Stura I, Migliaretti G, Porpiglia F.
Total anatomical reconstruction during robot-assisted radical prostatectomy: focus on urinary continence recovery and related complications after 1000 procedures.
BJU Int. 2019 Feb 23. doi: 10.1111/bju.14716. [Epub ahead of print]
Source | Full text | Similar articles



.

Saad F.
Quality of life in men with prostate cancer.
Lancet Oncol. 2019 Mar;20(3):325-326. doi: 10.1016/S1470-2045(18)30863-5. Epub 2019 Jan 31.
Source | Full text | Similar articles
Referring to: Downing A et al., Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. Lancet Oncol. 2019 Mar;20(3):436-447. doi: 10.1016/S1470-2045(18)30780-0. Epub 2019 Jan 31. Source , Full text



INTEGRATIVE MEDICINE

.

Slade AN.
Prostate cancer and subsequent nutritional outcomes: the role of diagnosis and treatment.
J Cancer Surviv. 2019 Feb 7. doi: 10.1007/s11764-019-00739-z. [Epub ahead of print]
Source | Full text | Similar articles



.

Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjan B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayaratne PR, Matzaris M, Montgomery MK, Papargiris M, Norden S,
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer.
Sci Transl Med. 2019 Feb 6;11(478). pii: eaau5758. doi: 10.1126/scitranslmed.aau5758.
Source | Full text | Similar articles



PROGNOSIS

.

Abdel-Rahman O.
Outcomes of Prostatectomy versus Radiation Therapy in the Management of Clinically Localized Prostate Cancer Patients Within the PLCO Trial.
Clin Genitourin Cancer. 2019 Jan 4. pii: S1558-7673(19)30004-7. doi: 10.1016/j.clgc.2018.12.010. [Epub ahead of print]
Source | Full text | Similar articles



.

Bravi CA, Tin A, Vertosick E, Mazzone E, Martini A, Dell'Oglio P, Stabile A, Gandaglia G, Fossati N, Suardi N, Gallina A, Briganti A, Montorsi F, Vickers A.
The Impact Of Experience On The Risk Of Surgical Margins And Biochemical Recurrence After Robot-Assisted Radical Prostatectomy: A Learning-Curve Study.
J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000147. [Epub ahead of print]
Source | Abstract | Similar articles



.

Casale P, Saita A, Lazzeri M, Lughezzani G, Hurle R, Fasulo V, Mondellini GM, Paciotti M, Domanico L, Lista G, Maffei D, Monari M, Motta L, Bini V, Ceriotti F, Guazzoni G, Buffi N.
[-2]proPSA for predicting biochemical recurrence of prostate cancer earlier than total PSA after radical prostatectomy: an observational prospective cohort study.
Minerva Urol Nefrol. 2019 Jan 28. doi: 10.23736/S0393-2249.19.03279-X. [Epub ahead of print]
Source | Abstract | Similar articles



.

Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N.
Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.
Urol Oncol. 2019 Feb 13. pii: S1078-1439(19)30050-X. doi: 10.1016/j.urolonc.2019.01.029. [Epub ahead of print]
Source | Full text | Similar articles



.

Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR.
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.
JAMA Netw Open. 2019 Feb 8;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006.
Source | Full text | Similar articles



.

Peng C, Zhang J, Hou J.
Performance characteristics of prostate-specific antigen density and biopsy primary Gleason score to predict biochemical failure in patients with intermediate prostate cancer who underwent radical prostatectomy.
Cancer Manag Res. 2019 Feb 1;11:1133-1139. doi: 10.2147/CMAR.S190443. eCollection 2019.
Source | Full text | Similar articles



.

Porcaro AB, Tafuri A, Sebben M, Cacciamani G, Ghimenton C, Brunelli M, Petrozziello A, Monaco C, Migliorini F, Siracusano S, Artibani W.
Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease.
Urol Int. 2019 Feb 14:1-9. doi: 10.1159/000496833. [Epub ahead of print]
Source | Full text | Similar articles



.

Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M, Huland H, Tilki D.
Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Eur Urol. 2019 Feb 13. pii: S0302-2838(19)30094-6. doi: 10.1016/j.eururo.2019.01.048. [Epub ahead of print]
Source | Full text | Similar articles



TREATMENT

.

Burki T.
Darolutamide for non-metastatic, castration-resistant prostate cancer.
Lancet Oncol. 2019 Mar;20(3):e139. doi: 10.1016/S1470-2045(19)30102-0. Epub 2019 Feb 21.
Source | Full text | Similar articles
Referring to: Fizazi K et al., Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019 Feb 14. doi: 10.1056/NEJMoa1815671. [Epub ahead of print] Source , Full text



.

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med. 2019 Feb 14. doi: 10.1056/NEJMoa1815671. [Epub ahead of print]
Source | Full text | Similar articles



bottom